Evidence map›Paper›PMID 37780610›Full record

ReviewFrontiers in endocrinology2023

Research progress on the role of the Wnt signaling pathway in pituitary adenoma.

Wencai Wang, Luyao Ma, Yongqiang Zhao, Menghao Liu, Wei Ye, Xianfeng Li

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wencai WangDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Luyao MaDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Yongqiang ZhaoDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Menghao LiuDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wei YeDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Xianfeng LiDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Second Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pituitary adenoma (PA) is the third most common central nervous system tumor originating from the anterior pituitary, but its pathogenesis remains unclear. The Wnt signaling pathway is a conserved pathway involved in cell proliferation, Self-renewal of stem cells, and cell differentiation. It is related to the occurrence of various tumors, including PA. This article reviews the latest developments in Wnt pathway inhibitors and pathway-targeted drugs. It discusses the possibility of combining Wnt pathway inhibitors with immunotherapy to provide a theoretical basis for the combined treatment of PA.

Indexed as

Pituitary NeoplasmsWnt Signaling PathwayCell DifferentiationHumansStem Cellsnon-coding RNAPAtargeted drugsTMEWnt pathway inhibitorsWnt signaling pathway

Identifiers

PMID37780610
PMCPMC10538627
OpenAlexW4386731715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.